In order to counteract the development of drug-resistant tuberculosis, new chemotherapy regimen based on novel anti-mycobacterial drugs are urgently needed. Bedaquiline (BDQ), formerly known as TMC207, showed strong potency in clinical trials, 1 and recently received approval by the US Food and Drug Administration and by the European Commission for treatment of multidrug-resistant tuberculosis. BDQ acts as specific inhibitor of mycobacterial ATP synthase, 2,3 an essential enzyme in mycobacterial energy metabolism 4 that uses the energy of a proton motive force across the bacterial plasmatic membrane for synthesis of ATP. 5 It has been hypothesized that an inhibitor of ATP synthesis, such as BDQ, may interfere with drug efflux. 6-8 Active efflux mediated by efflux pumps has been implied for resistance to antibacterial drugs in Mycobacterium tuberculosis 9,10 and in the non-pathogenic model strain M. smegmatis. 11,12 Prevention of drug efflux therefore may significantly enhance the potency of anti-tubercular drugs. 9,10 Efflux pumps are membrane transporters that can extrude a broad range of potentially harmful small molecules from the bacterial cytoplasma or periplasma. These pumps utilize the energy of either ATP (primary transporters or ATP-dependent efflux pumps) or the proton motive force (secondary transporters) for drug extrusion. An inhibitor of ATP synthesis, which depletes cellular ATP reserves, may concomitantly indirectly inactivate ATP-dependent efflux pumps.
(50 ml) at 37 1C to an OD 600 of 0.8. The culture was aliquoted and treated with different concentrations of BDQ or other antibacterials as controls. After the treatment, the culture was centrifuged at 13 000 r.p.m. for 3 min, and the pellet was washed twice and resuspended in phosphate-buffered saline. After adjusting the OD to 0.4, glucose and ethidium bromide were added to the bacterial suspension (final concentrations 0.4% and 1 mg ml À1 , respectively). Ethidium bromide fluorescence was measured for 45 min at excitation and emission wavelengths of 530 and 600 nm 11 using a Cary Eclipse Fluorescence spectrophotometer (Varian Inc., Midddelburg, The Netherlands) equipped with a plate heater set at 37 1C. Cellular ATP levels were determined using the luciferase bioluminescence method described previously. 13 In brief, 1.0 ml samples taken from bacterial cultures grown and treated with antibacterials as described above were centrifuged at 8000 g for 10 min. The pellets were resuspended in 50 ml water, and a 10-fold volume of boiling 100 mM Tris-HCl and 4 mM EDTA (pH 7.75) was added. After incubation at 100 1C for 2 min, the samples were centrifuged (1000 g, 60 s) and the supernatants were transferred to fresh tubes. A quantity of 100 ml luciferase reagent (ATP Bioluminescence assay, Roche, Basel, Switserland) was added to 100 ml sample, and luminescence was measured with a Luminometer (LKB, Turku, Finland).
In order to elucidate the impact of BDQ on small-molecule efflux, we determined the intracellular levels of ethidium bromide in M. smegmatis during the initial days of BDQ treatment. M. smegmatis displays similar susceptibility to BDQ as M. tuberculosis (MIC 90 is 0.007 mg l À1 for M. smegmatis and 0.03 mg l À1 for M. tuberculosis 2 ). Ethidium bromide is widely used as fluorescent reporter for assessment of efflux function in bacteria. 11, 12 For bacteria that were grown in the absence of BDQ, the ethidium bromide fluorescence increased with time until saturation, when equilibrium was reached between ethidium bromide influx and efflux ( Figure 1a) . As a control, addition of the efflux pump inhibitor verapamil to the assay mixture increased cellular ethidium bromide levels (Figure 1a) , as reported previously. 11 M. smegmatis treated with BDQ for 2 days also displayed enhanced ethidium bromide fluorescence ( Figure 1a ). The increase was dose dependent, and bacteria treated with 10 Â or 100 Â MIC showed significantly elevated ethidium bromide levels (450% fluorescence enhancement at 45 min time point), whereas samples at 1 Â MIC BDQ resembled the untreated control (Figure 1a ). This result indicates that BDQ interferes with ethidium bromide efflux. The effect is BDQ specific, as typical front-line antibacterials such as RIF (10 Â MIC) and INH (10 Â and 100 Â MIC) did not cause any efflux inactivation under the same conditions (Figure 1a ; MICs of M. smegmatis for RIF and INH are 32 and 4 mg l À1 , respectively).
We investigated whether inactivation of ethidium bromide efflux depends on the duration of BDQ treatment. Ethidium bromide efflux in M. smegmatis treated with BDQ (10 Â MIC) decreased with increasing duration of treatment. While only a minor efflux decrease was observed after 1 day, the effect was significantly more pronounced after 2 and 3 days of treatment (Figure 1b) . In controls, INH and RIF did not decrease efflux on any of the 3 days investigated (Figure 1b) . The results are consistent with the view that the decline of ethidium bromide efflux is caused by slow inactivation of efflux pumps. ATPdriven efflux pumps may become inactivated because of draining their energy source upon inhibition of ATP synthase by BDQ. Alternatively, potential downregulation of efflux pumps, as observed in a recent proteome study for M. tuberculosis in response to BDQ, 14 may contribute to the observed efflux decrease. Depletion of cellular ATP pools in M. tuberculosis occurs gradually within the initial days of BDQ treatment. 14 We tested whether BDQ has a similar effect on M. smegmatis and whether the reduction of bacterial ATP pools in the initial days of treatment correlates with the efflux decrease. As depicted in Figure 2 , BDQ induced approximately a 10-fold decline of cellular ATP levels in M. smegmatis after 2 days of treatment at 10 Â or 100 Â MIC ( Figure 2 ). As control, INH, an inhibitor of cell envelope biosynthesis, did not decrease bacterial ATP levels ( Figure 2 ). Cellular ATP levels in mycobacteria typically are in the range of 2-5 mM. 13, 15 Reduction of ATP levels by B10-fold may thus well interfere with the activity of ATP-dependent efflux pumps, which typically display K M values of 0.1-1 mM. 16, 17 For this reason, we regard it as likely that the inactivation of efflux in the presence of BDQ is at least in part caused by inactivation of ATP-driven efflux pumps owing to depletion of their energy supply.
This inactivation of drug efflux may in part explain why BDQ can suppress the emergence of resistance to front-line anti-tuberculosis drugs. 18 Other drugs targeting components of energy metabolic pathways in mycobacteria, such as the phenothiazines or imidazopyridines, 8, 19, 20 may display similar properties to BDQ in terms of interfering with efflux by depleting bacterial energy reserves. This principle may also be applicable in non-mycobacterial pathogenic strains, as recently derivates of BDQ with potency against Gram-positive bacterial pathogens have been found. 6 
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